PSMA PET Scan for Prostate Cancer: Uses, Preparation and Cost in India

A PSMA PET scan is one of the most important imaging tests used in modern prostate cancer care. It can help doctors locate prostate cancer cells that may be too small or difficult to identify with conventional imaging such as CT scans or bone scans.

PSMA stands for prostate-specific membrane antigen. It is a protein found on normal prostate cells and is often present at much higher levels on prostate cancer cells. A small amount of radioactive PSMA-targeting tracer is injected into a vein. The tracer attaches to PSMA-expressing cells and allows a PET scanner to identify areas of abnormal uptake.

PSMA PET is particularly useful when doctors need to determine whether prostate cancer has spread, find cancer that has returned after treatment, or assess disease that is not clearly visible on conventional imaging. How that sits with PSA, MRI and biopsy is covered in Prostate Cancer Diagnosis. How stage grouping uses the result is in Prostate Cancer Stages 1 to 4.

It can influence treatment planning, but it is not a standalone test that diagnoses or rules out prostate cancer in every situation. The scan must be interpreted together with PSA, biopsy results, Gleason score or Grade Group, MRI, previous treatment and other clinical information.

This is the dedicated PSMA PET hub for the prostate cluster. It sits beside diagnosis, Lu-177 PSMA therapy, recurrence after surgery, radiation and Prostate Cancer Treatment in India.

International patients comparing medical oncologists, radiation oncologists and surgical oncologists commonly start with Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. Partner medical-oncology hospitals in Delhi NCR and surgical hospitals in Mumbai are a typical first filter.

PSMA PET is a form of molecular imaging. Unlike a conventional CT scan, which primarily shows anatomy, PSMA PET provides information about the biological behaviour of tissues by showing where a PSMA-targeting radiotracer accumulates.

The examination usually combines PSMA radiotracer + PET imaging + CT imaging. The PET component identifies areas of tracer uptake. The CT component provides anatomical detail and helps doctors determine exactly where that uptake is located.

This combination makes it possible to detect and localize prostate cancer in lymph nodes, bones and other sites throughout the body.

PSMA = Prostate-Specific Membrane Antigen. Despite its name, PSMA is not found exclusively in prostate cancer. It is also present at lower levels in some normal tissues and can be expressed in certain other diseases and cancers.

This matters because PSMA uptake does not automatically mean prostate cancer. Normal structures such as the kidneys, salivary glands, bladder, small bowel and spleen can show physiological tracer uptake. Some non-prostate conditions can also produce abnormal uptake.

That is why the scan needs to be interpreted by an experienced nuclear medicine physician or radiologist rather than by looking at isolated bright spots on the images.

The major uses are initial staging, biochemical recurrence, persistent PSA after treatment, suspected metastatic disease, treatment planning, assessment before selected PSMA-targeted therapy, and selected cases where conventional imaging is inconclusive. The exact indication depends on the patient's risk category and clinical situation.

After prostate cancer is diagnosed, doctors need to determine whether the cancer is confined to the prostate, involving nearby lymph nodes, spread to bones, spread to distant lymph nodes, or present in other organs. This process is called staging. See Stages 1 to 4.

PSMA PET/CT can be particularly useful for men with unfavourable intermediate-risk, high-risk or locally advanced prostate cancer. The 2026 EAU guidelines recommend PSMA PET/CT, where available, for metastatic screening in high-risk localized or locally advanced prostate cancer. For unfavourable intermediate-risk disease, the guideline recommends PSMA PET/CT where available to increase staging accuracy.

No. A PSMA PET scan is not automatically required for every man with prostate cancer. Men with low-risk localized prostate cancer generally do not need extensive metastatic imaging simply because they have received a cancer diagnosis. The value increases when the probability of lymph-node or distant disease is higher or when the result is likely to change treatment.

Doctors consider PSA, Grade Group, Gleason score, clinical stage, MRI findings, biopsy results, symptoms and other risk factors before ordering the scan. Selected low-risk men may instead be on active surveillance.

One of the most important uses of PSMA PET is investigating biochemical recurrence. After radical prostatectomy, PSA is expected to become very low or undetectable. If PSA subsequently rises, doctors may suspect recurrent prostate cancer. The key question becomes: where is the cancer?

It may be in the prostate bed, pelvic lymph nodes, distant lymph nodes, bones or another metastatic site. PSMA PET can help locate recurrent disease and distinguish patients who may have disease confined to the pelvis from those who already have distant spread. The full recurrence pathway is in Prostate Cancer Recurrence After Surgery.

There is no single PSA value at which the scan suddenly becomes useful or useless. Detection generally becomes more likely as PSA rises, but PSMA PET can detect disease even at relatively low PSA levels.

The 2026 EAU guideline recommends PSMA PET/CT after radical prostatectomy when PSA is above 0.2 ng/mL and the result could influence subsequent treatment decisions. The decision may also consider PSA doubling time, Gleason score, Grade Group, surgical margins, pathological stage, previous imaging and whether salvage treatment is being considered.

PSMA PET can also be useful when PSA rises after radiation therapy. After radiation, the prostate remains in place, so PSA does not necessarily become undetectable. Doctors use specific criteria to determine biochemical recurrence after radiotherapy.

When recurrence is suspected, PSMA PET can help identify local recurrence in the prostate, pelvic lymph nodes, distant lymph nodes, bone metastases or other distant disease. The EAU recommends PSMA PET/CT in patients who are fit for potentially curative salvage treatment after biochemical recurrence following radiotherapy. Brachytherapy is a different radiation method; the same recurrence question can still apply.

Prostate cancer commonly spreads to pelvic lymph nodes, retroperitoneal lymph nodes, bones, more distant lymph nodes and, less commonly, organs such as the liver or lungs. PSMA PET can identify many of these sites. This can be particularly valuable when conventional CT or bone imaging is negative or uncertain despite a clinical suspicion of metastatic disease. Urinary or bone symptoms do not by themselves set the scan indication.

PSMA PET is not simply a “better CT.” It is a different type of imaging that combines molecular information with CT anatomy.

A conventional bone scan looks for changes in bone metabolism. PSMA PET looks for PSMA expression associated with prostate cancer. A bone scan can identify bone abnormalities caused by several processes, while PSMA PET can provide more direct molecular information related to prostate cancer.

In the prospective ProPSMA trial summarized by the EAU, PSMA PET/CT had higher accuracy than conventional CT plus bone scanning for staging men with high-risk prostate cancer. However, PSMA PET is not perfect. Very small lesions can still be missed.

MRI and PSMA PET are complementary. MRI is particularly useful for local prostate anatomy, tumour location within the prostate, extraprostatic extension, seminal-vesicle involvement, local recurrence assessment and biopsy targeting. PSMA PET is particularly useful for whole-body staging, lymph-node assessment, bone metastases, distant disease and biochemical recurrence. In selected situations, doctors may use both. See diagnosis.

Usually, no. A biopsy provides histological confirmation by examining prostate tissue under a microscope. PSMA PET provides imaging information. A PSMA-avid lesion can be highly suspicious for cancer, but imaging alone does not automatically establish the same pathological information that a biopsy provides.

The EAU currently recognizes an evolving role for PSMA PET in prostate cancer diagnosis and notes that it may help guide targeted biopsy in selected circumstances.

Yes. PSMA PET can show areas within the prostate with increased PSMA expression. However, prostate MRI remains a major tool for local assessment. Research into combining PSMA PET with MRI is ongoing, and the EAU notes evidence that combined approaches can improve diagnostic performance in selected settings.

The radiotracer is a small radioactive molecule designed to bind to PSMA. Different centres may use different tracers depending on regulatory approvals, availability, hospital facilities, local nuclear medicine infrastructure, and production and transport logistics.

Examples include Gallium-68 PSMA and Fluorine-18 PSMA tracers. The exact tracer should be recorded in the scan report because imaging protocols and interpretation can vary. For a patient travelling internationally, confirm which tracer the centre uses before booking.

Gallium-68 PSMA is widely used in prostate cancer imaging. It has been extensively studied for initial staging, biochemical recurrence, metastatic disease and treatment planning. Several Indian cancer centres offer Ga-68 PSMA PET/CT as part of prostate cancer imaging services.

Fluorine-18-labelled PSMA tracers are another important option. Some F-18 tracers have longer physical half-lives than Ga-68 tracers, which can influence production and distribution logistics.

Preparation is generally simpler than preparation for some other PET examinations. Instructions vary depending on the tracer and hospital protocol. Your imaging centre's instructions should always take priority.

Should you fast? Not necessarily. Do not assume that the fasting instructions for an FDG PET scan automatically apply to PSMA PET. Can you drink water? Usually yes, unless fluid is restricted for another medical reason. Can you take regular medicines? In many cases yes, unless the care team instructs otherwise. Do not independently stop medication before a scan.

Plan for approximately 2–3 hours at the imaging centre. The time includes registration, IV placement, tracer injection, uptake period, PET/CT imaging and immediate post-scan instructions. The actual imaging component is generally much shorter than the total appointment. International patients should therefore avoid scheduling another appointment immediately after the scan.

The scan itself is painless. The only significant discomfort for most patients is the insertion of the IV cannula. You need to remain still during imaging. Patients who have difficulty lying flat or have severe claustrophobia should tell the imaging team in advance.

PSMA PET involves exposure to a small amount of ionizing radiation from the radiotracer and CT component. The test is generally considered safe when clinically indicated. The tracer is present in the body temporarily and is eliminated over time. As with any radiopharmaceutical examination, the decision to perform the scan should consider whether the expected diagnostic benefit justifies radiation exposure.

Most patients tolerate PSMA tracers well. Serious reactions are uncommon. Tell the imaging team about drug allergies, previous radiotracer reactions, relevant kidney problems and other significant health conditions.

The radiation exposure from a medically indicated diagnostic PSMA PET/CT is relatively small compared with the potential benefit of obtaining important staging or recurrence information. Radiation exposure is cumulative, so unnecessary scans should be avoided.

A PSMA PET report usually contains a detailed description followed by an impression or conclusion. It may describe prostate or prostate-bed findings, lymph nodes, bone lesions, visceral organs, other incidental findings and areas of physiological tracer uptake. It may also report an SUV.

SUV stands for Standardized Uptake Value. It is a quantitative measurement that describes how much radiotracer is concentrated in a particular area. A higher SUV means greater tracer accumulation. A higher SUV does not automatically mean a more aggressive cancer. SUV must be interpreted according to the tracer used, location, size of lesion, background activity, CT and MRI findings and clinical history. SNMMI specifically cautions that tracer uptake does not always mean cancer.

If a report describes a lesion as PSMA-avid, it means that the lesion shows increased uptake of the PSMA-targeting radiotracer. This can make the lesion suspicious for prostate cancer. The meaning depends on its location and appearance. PSMA uptake in the kidneys and salivary glands can be normal.

A positive scan means that the imaging findings are suspicious for PSMA-expressing disease. It may show prostate tumour, pelvic lymph-node disease, distant lymph-node disease, bone metastases or other metastatic lesions. The clinical significance depends on the exact location and pattern.

A negative PSMA PET means that no suspicious PSMA-avid disease was identified within the limits of the examination. It does not guarantee that there are no cancer cells anywhere in the body. Very small lesions may be below the spatial resolution of PET. Some prostate cancers also express relatively little PSMA and may therefore be less visible.

Yes, both can occur. False-positive findings can occur because PSMA expression is not completely exclusive to prostate cancer. Inflammatory processes and some other benign or malignant conditions can produce PSMA uptake.

No imaging test detects every cancer deposit. SNMMI notes that tumours smaller than approximately 0.5 cm may not always be visible. The EAU notes that small lymph-node metastases below PET's spatial resolution may remain undetected. Therefore: a negative PSMA PET does not automatically mean there is no prostate cancer.

It can detect many lymph-node metastases, including some that are difficult to identify on conventional imaging. Very small metastatic deposits can still be missed. This is important when deciding whether a patient requires additional treatment such as pelvic lymph-node dissection.

Bone is one of the most important sites of metastatic prostate cancer. PSMA PET can identify many bone metastases and can also help distinguish prostate-cancer-related lesions from other findings. Interpretation requires attention to lesion location, CT appearance and tracer uptake.

Biochemical recurrence means that PSA has risen after definitive treatment. PSMA PET has become particularly important in this setting because the scan can sometimes locate recurrence when conventional imaging is still negative. This can change the treatment pathway.

The EAU reports that PSMA PET/CT can substantially change management intent in selected patients with biochemical recurrence. The likelihood of finding recurrent disease generally increases as PSA rises, but PSMA PET can identify disease at relatively low PSA levels, including below 0.5 ng/mL after prostatectomy. The decision to scan should nevertheless be based on whether the result is likely to affect management.

Men with high-risk prostate cancer have a greater possibility of lymph-node or distant disease. PSMA PET can therefore provide important staging information before deciding between surgery, radiation, hormone therapy, combination treatment or systemic treatment. The 2026 EAU guideline recommends PSMA PET/CT where available for metastatic screening in high-risk localized and locally advanced prostate cancer.

Yes. This is one of the most clinically important benefits. A conventional CT and bone scan might suggest that cancer is confined to the prostate. PSMA PET may reveal previously undetected pelvic lymph nodes, distant lymph nodes, bone metastases or other metastatic sites.

The ProPSMA trial found greater accuracy with PSMA PET/CT compared with conventional imaging and reported more frequent management changes in the PSMA PET group. Detecting more lesions does not automatically mean that every management change improves survival. The scan should therefore be used within an evidence-based treatment pathway. See treatment options.

PSMA PET may be considered in selected men before radical prostatectomy, particularly when there is a meaningful risk of lymph-node or distant disease. A negative scan does not eliminate the possibility of microscopic disease. Surgical decisions should not be based solely on a negative PSMA PET result. GAF Healthcare planning ranges for radical prostatectomy in India are $7,000–$18,000, including city pages such as Delhi NCR prostatectomy.

Before radiation, PSMA PET can help determine whether disease extends beyond the prostate and may influence radiation-field design and whether additional systemic therapy is needed. Planning ranges include EBRT $1,000–$6,000+, IMRT $6,500–$14,500 and brachytherapy $5,500–$13,000.

When PSA rises after prostatectomy, PSMA PET can help determine whether recurrent disease is confined to the prostate bed, present in pelvic nodes, present outside the pelvis, or widely metastatic. The EAU specifically recommends PSMA PET when its results could influence treatment decisions in biochemical recurrence.

PSMA PET is also important in PSMA-targeted radioligand therapy. Lutetium-177 PSMA therapy uses a radioactive treatment molecule designed to bind to PSMA-expressing cancer cells. Before treatment, imaging may be used to determine whether the cancer demonstrates sufficient PSMA expression to make PSMA-directed therapy appropriate.

Therefore, PSMA PET has evolved from being purely diagnostic imaging to also playing a role in selecting patients for certain targeted radioligand treatments. The EANM/SNMMI procedure guideline specifically identifies staging before PSMA radioligand therapy as an important clinical indication.

PSMA PET can sometimes be used to assess treatment response or progression. However, it is not automatically repeated after every treatment cycle. Usefulness depends on treatment type, disease stage, PSA response, symptoms, clinical trial protocol and whether the result will change treatment. The EAU notes that the role of PSMA PET in monitoring systemic treatment is evolving and should be interpreted carefully in advanced disease.

Yes. Hormonal treatment can influence PSMA expression and therefore tracer uptake. PSMA expression may increase temporarily after some forms of androgen deprivation, while treatment response and disease biology can also affect imaging appearance.

The radiology/nuclear medicine team needs to know whether you are taking ADT, which hormone medicine you are taking, when the treatment started, whether you are receiving chemotherapy, whether you have recently received radiation, and whether you have had previous PSMA imaging. PSMA PET should never be interpreted without knowing the treatment context. Hormone therapy planning ranges on this site are $1,000–$4,500.

The cost of a PSMA PET/CT scan in India is commonly around ₹15,000–₹30,000, according to the indicative price published by Apollo Hospitals. For international planning that is roughly $180–$360 at current conversion — an illustration, not a GAF catalog quotation. GAF Healthcare does not publish a dedicated PSMA PET cost page.

This should not be treated as a universal national price. The actual quotation can vary depending on city, hospital, nuclear medicine department, type of PSMA tracer, availability, PET/CT equipment, whether contrast CT is included, reporting fees, additional imaging, urgent versus routine scheduling and radiopharmaceutical availability.

For international patients, it is better to ask for a written quotation specifying exactly what is included. Adjacent treatment planning ranges on this site remain chemotherapy $1,500–$8,000+ if systemic therapy follows the scan.

Prices can vary even within the same city. International patients commonly consider major medical centres in Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad (GAF partner cities), as well as other Indian centres such as Kolkata, Pune and Ahmedabad when a local quotation is already in hand.

Rather than relying on a generic online price, confirm which tracer is being used, whether the tracer and contrast CT are included, whether the nuclear medicine reporting fee is included, how quickly the report will be available, whether the centre will provide DICOM images, and whether a specialist consultation is included.

A package may include nuclear medicine consultation, radiotracer, IV administration, PET/CT scan, image interpretation and a written report. It may not include oncologist consultation, MRI, biopsy, contrast charges, additional laboratory tests, accommodation, travel or follow-up consultation. International patients should clarify these details before payment.

Patients travelling to India specifically for PSMA PET should plan the visit around the scan rather than arriving without an appointment.

For recurrence cases, the PSA timeline is particularly useful.

The scan itself is only one part of the decision-making process. The treating doctor may combine the findings with PSA, PSA doubling time, Gleason score, Grade Group, pathology, MRI, previous treatment, symptoms and overall health.

The result may lead to no immediate treatment change, additional MRI, biopsy, salvage radiation, surgery, hormone therapy, systemic treatment, metastasis-directed treatment, or PSMA-targeted radioligand therapy assessment. See treatment without surgery when prostatectomy is not the next step.

For many prostate cancer staging situations, PSMA PET/CT provides more comprehensive molecular information and can be more accurate than conventional CT plus bone scanning. The ProPSMA trial found substantially higher accuracy for PSMA PET/CT compared with conventional imaging in high-risk staging. “Better” does not mean that bone scans have no role. Availability, clinical context, cost and treatment setting still matter.

CT remains valuable for anatomical assessment. In many prostate cancer staging situations, the two are combined as PSMA PET/CT rather than treated as competing tests.

PSMA PET refers to the molecular PET component. PSMA PET/CT combines PET with CT. This is why PSMA PET/CT is currently the common term patients encounter when booking the examination. PSMA PET/MRI is available at a smaller number of centres and can add MRI soft-tissue detail.

The biggest value of PSMA PET is not simply that it produces a more detailed image. Its value is that it can answer a clinically important question: where is the prostate cancer?

For a newly diagnosed high-risk patient, that may mean determining whether the cancer has already spread. For a patient after prostatectomy, it may mean finding the source of a rising PSA. For someone after radiation, it may distinguish local recurrence from metastatic disease. For a patient being considered for PSMA-targeted treatment, it may help establish whether the cancer expresses the target needed for that therapy.

At the same time, PSMA PET has limitations. It should not be interpreted as a perfect cancer detector, and a scan result should never be separated from the patient's PSA, pathology, previous treatment and clinical history.

PSMA PET/CT is an advanced molecular imaging test that can locate prostate cancer with greater sensitivity than conventional imaging in many important clinical settings.

It is particularly useful for staging higher-risk prostate cancer, detecting lymph-node and bone metastases, investigating rising PSA after prostatectomy, evaluating recurrence after radiation, planning salvage treatment, and assessing selected patients for PSMA-targeted radioligand therapy.

Preparation is usually straightforward. Most patients can continue their normal medicines unless specifically instructed otherwise, and fasting requirements vary by centre and tracer.

In India, an indicative PSMA PET/CT cost is around ₹15,000–₹30,000, although the actual price can vary substantially depending on the hospital, city, tracer and services included.

For international patients, the most important step is not simply finding the cheapest scan. It is confirming that the centre has the appropriate PSMA tracer, experienced nuclear medicine team, reliable reporting and access to the full digital images needed by the treating oncologist.

No. It is most useful when the scan is likely to answer an important staging, recurrence or treatment-planning question.

There is no universal PSA threshold. The decision depends on the treatment history, PSA trend, cancer risk and whether the scan will change management. After prostatectomy, the 2026 EAU guideline recommends PSMA PET/CT when PSA is above 0.2 ng/mL if the result could influence treatment.

Yes. Detection is possible even at relatively low PSA levels, although the probability of finding disease generally increases as PSA increases.

Not necessarily. Preparation varies by centre and tracer. Many patients can eat normally, but follow the instructions from the imaging centre.

Usually yes. Hydration is commonly encouraged, but patients with fluid restrictions should follow their doctor's advice.

Usually, routine medicines can be continued unless the imaging team tells you otherwise.

The complete appointment often takes about 2–3 hours. The actual scan may take around 30 minutes after the tracer uptake period.

The scan itself is painless. Most patients only feel the brief discomfort associated with IV placement.

It is generally well tolerated, but it involves exposure to ionizing radiation. The decision to perform it should be based on a clinical indication.

It means an area has increased uptake of the PSMA-targeting tracer. It does not automatically prove that the area is prostate cancer.

Yes. Bone is a common site of prostate cancer spread, and PSMA PET can identify many bone metastases.

Yes, including some lymph-node metastases that are difficult to identify on conventional CT. Very small deposits can still be missed.

Yes. It is particularly useful when PSA rises after radical prostatectomy and recurrent disease needs to be localized.

Yes. It can identify local and distant recurrent disease and may help determine whether salvage treatment is appropriate.

No. MRI and PSMA PET provide complementary information.

Generally, no. Imaging and histopathology provide different types of information.

Yes. Very small lesions or tumours with low PSMA expression may not be detected.

Yes. Some benign and non-prostate malignant conditions can show PSMA uptake.

An indicative price range published by Apollo Hospitals is ₹15,000–₹30,000. Actual prices vary by hospital, city, tracer and services included.

The scan itself is usually completed within one appointment, but international patients should allow additional time for specialist consultation, review of previous reports and treatment planning if the scan is being performed as part of a larger cancer evaluation.

Yes. PSMA imaging can be used to determine whether a patient's cancer demonstrates sufficient PSMA expression for consideration of PSMA-targeted radioligand therapy.

This article is the PSMA PET hub. Other cluster pages keep their own search intent:

GAF Healthcare coordinates international patients who need a PSMA PET/CT in India as part of staging, a rising PSA, or a Lu-177 work-up. Share the PSA timeline, the full biopsy PDF, MRI and previous PET files rather than printed summaries only, and the treatment history including ADT. A coordinator can introduce a medical oncologist, radiation oncologist or uro-oncologist, then help collect a written quotation that states the tracer, whether contrast CT is included, report time and DICOM access.

This article is for educational purposes and does not replace medical consultation. The decision to perform a PSMA PET scan depends on the patient's diagnosis, PSA level and trend, cancer risk group, previous treatment, imaging findings and intended treatment plan.

A PSMA PET result should be interpreted by an appropriately qualified nuclear medicine physician or radiologist together with the treating urologist or oncologist. Patients should not make treatment decisions based solely on an imaging report.

1. EAU Guidelines — Diagnostic Evaluation of Prostate Cancer — PSMA PET/CT for initial staging, biochemical recurrence and metastatic assessment.

2. EAU Guidelines — Prostate Cancer Treatment — PSMA PET/CT in biochemical recurrence and treatment planning.

3. SNMMI — PSMA PET/CT for Prostate Cancer Patients — patient-focused explanation of tracers, the scanning process, uptake and limitations.

4. SNMMI/EANM — PSMA PET/CT Procedure Guideline — indications, staging, recurrence and assessment before PSMA-targeted radioligand therapy.

5. Apollo Hospitals — PSMA PET/CT Scan — practical information on preparation, procedure and an indicative India cost range.

Last reviewed against the cited sources: September 2026.